MHRA-101226-PIP01-23

Key Facts

Active Substance
Active Substance:
  • Volrustomig
Invented Name
Volrustomig
PIP Number MHRA-101226-PIP01-23
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Concentrate for solution for injection/infusion
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
  • Treatment of cervical cancer
  • Treatment of renal cell carcinoma
  • Treatment of lung cancer
  • Treatment of mesothelioma
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Volrustomig.pdf
Published Date 24/06/2024